XDR SHIGELLA US EMERGENCE — CDC MMWR APRIL 2026
Title: "Emergence of Extensively Drug-Resistant
Currently interpreted as supporting evidence for 13 tracked assessments.
Public note
For situational awareness and research transparency. Not medical advice.
Needs resolution
This prediction reached its horizon without auto-resolution. Our synthesis agents are reviewing. Check back, or contribute your assessment.
System-generated assessment. This assessment remains under review until the stated horizon or until sufficient evidence allows evaluation.
Moderate confidence
The evidence is meaningful, but there is still material uncertainty. Based on 1 linked evidence item and assessed against 90D.
02
The criteria the system uses to determine whether this assessment is borne out by the stated horizon.
Method
The condition the system checks for when evaluating this assessment.
Minimum source quality
Evidence must meet or exceed this credibility tier to count toward evaluation.
Required terms
ceftriaxone-resistantphylogeneticallyinvestigationinternational03
Tracking since Apr 14, 2026.
06
The current analyst narrative for this scope.
AMR evidence coverage critically degraded this cycle; two hypotheses resolve in 5 days without supporting data; PubMed failure is the primary bottleneck.
07
1 linked item.
Currently interpreted as supporting evidence for 13 tracked assessments.
Integrity anchor
Brier 0.202
19 resolved novel pathogen detection predictions.